Abstract:Thrombotic thrombocytopenic purpura (TTP) is a particular form of thrombotic microangiopathy typically characterized by microangiopathic hemolytic anemia, profound peripheral thrombocytopenia, and a severe deficiency of the von Willebrand factor-cleaving protease ADAMTS13 (acronym for A Disintegrin And Metalloproteinase with ThromboSpondin-1 motifs [13th member of the family]). ADAMTS13 deficiency is usually severe (<10% of normal activity) and results from autoantibodies directed to ADAMTS13 (acquired TTP) or from biallelic mutations of the encoding gene. In some cases, acquired TTP occurs in association with specific conditions that must be identified for appropriate management: a HIV infection, a connective tissue disease, a pregnancy, a cancer or a treatment with antiplatelet agents. TTP requires a rapid diagnosis and an adapted management in emergency, which allows current remission rates of 80 to 90%. Maximal measures of resuscitation may be required. Daily sessions of therapeutical plasma exchange (TPE) until durable platelet count recovery remain the basis of management of acquired TTP. In the last few years, the anti-CD20 monoclonal antibody rituximab has been increasingly used in patients with a suboptimal response to standard treatment, such as those with refractory disease (∼10% of cases) or an exacerbation of the disease despite intensive TPE (∼50% of cases). Rituximab prevents 1-year but not long-term relapses. Further studies should specify the optimal schedule of rituximab administration and its role as a prophylactic treatment in asymptomatic patients with severe acquired ADAMTS13 deficiency that persists even in disease remission. In hereditary TTP, also known as Upshaw-Schulman syndrome (USS), a diagnosis early in life is mandatory. Prophylactic infusions of plasma should be performed in chronic relapsing forms to prevent long-term organ complications, which have to be assessed accurately and regularly. In the upcoming years, new targeted therapies evaluated through international trials should further improve the management of these diseases. Consensual guidelines for the treatment of very specific and rare situations (such as management during pregnancy in USS patients and prevention of relapses in chronic relapsing acquired TTP) should arise from the shared experience of national groups.

Acquired thrombotic thrombocytopenic purpura without detectable anti-ADAMTS13 antibodies: a possible underlying autoimmune mechanism

[A Clinical Study of Congenital Thrombotic Thrombocytopenic Purpura].

[Identification of Two Novel Mutations in ADAMTS13 Gene in a Patient with Hereditary Thrombotic Thrombocytopenic Purpura].

Diagnosis and management of acquired thrombotic thrombocytopenic purpura in southeast China: a single center experience of 60 cases

ADAMTS13 conformation and immunoprofiles in Japanese patients with immune-mediated thrombotic thrombocytopenic purpura

Current management and therapeutical perspectives in thrombotic thrombocytopenic purpura

ADAMTS‐13 Plasma Level Determination Uncovers Antigen Absence in Acquired Thrombotic Thrombocytopenic Purpura and Ethnic Differences

The Specificities of Thrombotic Thrombocytopenic Purpura at Extreme Ages: A Narrative Review

Atypical Presentations of Pediatric-acquired Thrombotic Thrombocytopenic Purpura

ADAMTS13 Biomarkers in Management of Immune Thrombotic Thrombocytopenic Purpura

Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura

Pathological Mechanisms and Novel Testing Methods in Thrombotic Thrombocytopenic Purpura

Clinical Characteristics of 83 Patients with Thrombotic Thrombocytopenic Purpura

Immature platelet dynamics correlate with ADAMTS13 deficiency and predict therapy response in immune-mediated thrombotic thrombocytopenic purpura

Laboratory Testing for ADAMTS13 for Thrombotic Thrombocytopenia Purpura and Beyond

Diagnostic Challenges in a Case of Immune-Mediated Thrombotic Thrombocytopenic Purpura With Severe ADAMTS13 Deficiency

Newly Developed ADAMTS13 Antigen Assay Reveals Marked Ethnic Differences and Depletion in Acquired Thrombotic Thrombocytopenic Purpura.

Acquired Thrombotic Thrombocytopenic Thrombocytopenia Presenting As Urinary Tract Infection and Perianal Abscess: A Case Review

The clinical studies of 51 patients with thrombotic thrombocytopenic purpura]

The utility of patient characteristics in predicting severe ADAMTS13 deficiency and response to plasma exchange

Clinical and Laboratory Features of Patients with Acquired Thrombotic Thrombocytopenic Purpura: Fourteen Years of the Milan TTP Registry